Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).
about
Non-alcoholic fatty liver disease: what the clinician needs to know.Current Management of NAFLDNAFLD and Chronic Kidney DiseaseNonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment optionsRole of diet on non-alcoholic fatty liver disease: An updated narrative reviewAssociation of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysisFrom NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?Genetic architecture of human fibrotic diseases: disease risk and disease progression.Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.Management of fatty liver disease with the metabolic syndrome.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Hypoxia and fatty liver.Renin angiotensin system in liver diseases: Friend or foe?Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study.Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
P2860
Q24563068-383C53E6-0B73-490C-BAB4-8FCF6741F8E1Q26752729-1C32B99F-ECA1-4B5D-AD77-5CACEFDC400BQ26752759-C824C69C-55CF-43C8-A44F-54DB75BCF540Q26796448-41B97756-E8BD-43A4-AB2A-2F1B7F5A171EQ27000333-78C04C5D-5981-4737-9725-171C4294BF23Q33932951-F15C3B75-B5F9-451B-8CFF-E4B8B25F9FCEQ36207195-77C5A3BB-5C44-49FB-846D-0670D641835DQ37400152-41FC69BD-2D2E-40F8-B966-43465DAA7294Q38160948-EE851243-9DC8-444A-B002-6326CF4150E5Q38199130-CB95822D-119B-4356-96CA-195F32A57986Q38261236-E0A4C2D6-3370-412C-8131-A30D4DE4FB01Q38266865-3A5769F5-2093-4708-A26A-9332DA7C2D90Q39360840-0A4EAD50-0940-42FD-89C7-EA7CA835336DQ41883631-D943E475-151E-4278-838C-DD65194F4B71Q45403785-EBCD935D-8411-4A2D-B712-8219DA858B58Q52584505-1F6AD788-A7E1-44A0-8133-319D0065C808Q53714410-FCD8DC73-FA21-473B-83B3-AE27325C500EQ55358328-391F191C-0BD7-44D8-95DF-B55722FEC79A
P2860
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of Telmisartan or Losar ...... n or Losartan Study (FANTASY).
@en
Effect of Telmisartan or Losar ...... Telmisartan or Losartan Study
@nl
type
label
Effect of Telmisartan or Losar ...... n or Losartan Study (FANTASY).
@en
Effect of Telmisartan or Losar ...... Telmisartan or Losartan Study
@nl
prefLabel
Effect of Telmisartan or Losar ...... n or Losartan Study (FANTASY).
@en
Effect of Telmisartan or Losar ...... Telmisartan or Losartan Study
@nl
P2093
P2860
P356
P1476
Effect of Telmisartan or Losar ...... n or Losartan Study (FANTASY).
@en
P2093
Akira Shimada
Hidetsugu Saito
Hirokazu Yokoyama
Hiroshi Hirose
Hiroshi Itoh
Hirotoshi Ebinuma
Junichiro Irie
Keisuke Ojiro
Kengo Tomita
Masahiro Kikuchi
P2860
P304
P356
10.1155/2013/587140
P577
2013-08-13T00:00:00Z